Skip to Main content Skip to Navigation
Journal articles

A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome

Abstract : Abstract There is currently no approved treatment for primary Sjögren’s syndrome, a disease that primarily affects adult women. The difficulty in developing effective therapies is -in part- because of the heterogeneity in the clinical manifestation and pathophysiology of the disease. Finding common molecular signatures among patient subgroups could improve our understanding of disease etiology, and facilitate the development of targeted therapeutics. Here, we report, in a cross-sectional cohort, a molecular classification scheme for Sjögren’s syndrome patients based on the multi-omic profiling of whole blood samples from a European cohort of over 300 patients, and a similar number of age and gender-matched healthy volunteers. Using transcriptomic, genomic, epigenetic, cytokine expression and flow cytometry data, combined with clinical parameters, we identify four groups of patients with distinct patterns of immune dysregulation. The biomarkers we identify can be used by machine learning classifiers to sort future patients into subgroups, allowing the re-evaluation of response to treatments in clinical trials.
Document type :
Journal articles
Complete list of metadata
Contributor : Geneviève Michel Connect in order to contact the contributor
Submitted on : Tuesday, July 27, 2021 - 4:37:59 PM
Last modification on : Monday, October 11, 2021 - 2:23:58 PM

Links full text




Cristina Bagacean, Cristina Adela Iuga, Anne Bordron, Adrian Tempescul, Ioana-Ecaterina Pralea, et al.. A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome. Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.3523. ⟨10.1038/s41467-021-23472-7⟩. ⟨hal-03301897⟩



Record views